Last reviewed · How we verify
Pf-08046045 (pf-08046045)
PF-08046045 is an investigational drug developed by Pfizer Inc. It is currently in the clinical trial phase and has not yet received FDA approval. The drug is being evaluated for its potential in treating specific cancers. Its mechanism of action involves targeting a specific protein involved in cancer cell proliferation. While detailed safety and efficacy data are still emerging, early trials have shown promising results. However, as it is not yet approved, there is limited public information available on its full profile.
At a glance
| Generic name | pf-08046045 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Small molecule inhibitor |
| Target | Specific protein involved in cancer cell proliferation |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | TBD |
Approved indications
- Indication not found
- Indication not found
Pipeline indications
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Clopidogrel
- P2Y12 inhibitors
- Dabigatran
- Rivaroxaban
- Apixaban
- Esomeprazole
- Omeprazole
- Lansoprazole
- Pantoprazole
- Rabeprazole
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pf-08046045 CI brief — competitive landscape report
- Pf-08046045 updates RSS · CI watch RSS
- Pfizer portfolio CI